

Ertugliflozin / Metformin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 4.1
 30.09.2023
 590558-00018
 Date of first issue: 01.04.2016

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Ertugliflozin / Metformin Formulation

Manufacturer or supplier's details

Company name of supplier : MSD

Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification

Acute toxicity (Oral) : Category 4

GHS label elements

Hazard pictograms



Signal Word : Warning

Hazard Statements : H302 Harmful if swallowed.

Precautionary Statements : Prevention:

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

Response:

P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER or doctor/ physician if you feel unwell. Rinse mouth.

Disposal:

P501 Dispose of contents/ container to an approved waste dis-

posal plant.

Other hazards

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture



Ertugliflozin / Metformin Formulation

Date of last issue: 04.04.2023 Version Revision Date: SDS Number: 4.1 30.09.2023 590558-00018 Date of first issue: 01.04.2016

Components

Chemical name	CAS-No.	Concentration (% w/w)
metformin hydrochloride	1115-70-4	>= 70 -< 90
Cellulose	9004-34-6	>= 10 -< 20
Magnesium stearate	557-04-0	>= 1 -< 5
Ertugliflozin	1210344-83-4	>= 0.1 -< 1

SECTION 4. FIRST AID MEASURES

General advice In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact Wash with water and soap.

Get medical attention if symptoms occur.

If in eyes, rinse well with water. In case of eye contact

Get medical attention if irritation develops and persists.

If swallowed If swallowed, DO NOT induce vomiting unless directed to do

> so by medical personnel. Get medical attention.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person.

Most important symptoms

and effects, both acute and

delayed

Harmful if swallowed.

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation. First Aid responders should pay attention to self-protection, Protection of first-aiders

> and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical None known.

Unsuitable extinguishing

media

Specific hazards during fire

fighting

Avoid generating dust; fine dust dispersed in air in sufficient

concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides

Nitrogen oxides (NOx)

Metal oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment.

Use water spray to cool unopened containers.



Ertugliflozin / Metformin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 4.1
 30.09.2023
 590558-00018
 Date of first issue: 01.04.2016

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable

container for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation Advice on safe handling Use only with adequate ventilation.

Do not breathe dust.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.



Ertugliflozin / Metformin Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 4.1 30.09.2023 590558-00018 Date of first issue: 01.04.2016

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

Conditions for safe storage : Keep in properly labeled containers.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
metformin hydrochloride	1115-70-4	TWA	1 mg/m3 (OEB 1)	Internal
Cellulose	9004-34-6	VLE-PPT	10 mg/m³	NOM-010- STPS-2014
		TWA	10 mg/m ³	ACGIH
Magnesium stearate	557-04-0	VLE-PPT	10 mg/m³	NOM-010- STPS-2014
		TWA (Inhalable particulate matter)	10 mg/m³	ACGIH
		TWA (Respirable particulate matter)	3 mg/m³	ACGIH
Ertugliflozin	1210344-83- 4	TWA	10 μg/m3 (OEB 3)	Internal
		Wipe limit	100 μg/100 cm ²	Internal

Engineering measures : All engineering controls should be implemented by facility

design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face

containment devices).

Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or

exposure assessment demonstrates exposures outside the

recommended guidelines, use respiratory protection.



Ertugliflozin / Metformin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 4.1
 30.09.2023
 590558-00018
 Date of first issue: 01.04.2016

Filter type Hand protection : Particulates type

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, diaposable quite) to evoid expended this purfoces.

disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Color : No data available

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing,

handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : Not applicable

Relative vapor density : Not applicable



Ertugliflozin / Metformin Formulation

Date of last issue: 04.04.2023 Version Revision Date: SDS Number: 4.1 30.09.2023 590558-00018 Date of first issue: 01.04.2016

Relative density No data available

Density No data available

Solubility(ies)

Water solubility No data available

Partition coefficient: n-

octanol/water

Not applicable

Autoignition temperature

No data available

Decomposition temperature No data available

Viscosity

Viscosity, kinematic Not applicable

Explosive properties Not explosive

Oxidizing properties The substance or mixture is not classified as oxidizing.

Particle size No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity Not classified as a reactivity hazard. Chemical stability Stable under normal conditions.

Possibility of hazardous reac-

tions

products

May form explosive dust-air mixture during processing,

handling or other means.

Can react with strong oxidizing agents.

Conditions to avoid Heat, flames and sparks.

Avoid dust formation.

Incompatible materials

Hazardous decomposition

Oxidizing agents No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Harmful if swallowed.

Product:

Acute oral toxicity Acute toxicity estimate: 1,337 mg/kg

Method: Calculation method



Ertugliflozin / Metformin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 4.1
 30.09.2023
 590558-00018
 Date of first issue: 01.04.2016

Components:

metformin hydrochloride:

Acute oral toxicity : LD50 (Rat): 1,000 mg/kg

LD50 (Mouse): 1,450 - 3,500 mg/kg

LD50 (Monkey): 463 mg/kg

LD50 (Rabbit): 350 mg/kg

LD50 (Guinea pig): 500 mg/kg

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 423

Assessment: The substance or mixture has no acute oral tox-

icity

Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Remarks: Based on data from similar materials

Ertugliflozin:

Acute oral toxicity : LD50 (Rat): 500 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Skin corrosion/irritation

Not classified based on available information.

Components:

metformin hydrochloride:

Species : Rabbit

Result : Mild skin irritation

Magnesium stearate:

Species : Rabbit

Result : No skin irritation



Ertugliflozin / Metformin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 4.1
 30.09.2023
 590558-00018
 Date of first issue: 01.04.2016

Remarks : Based on data from similar materials

Ertugliflozin:

Result : Corrosive

Serious eye damage/eye irritation

Not classified based on available information.

Components:

metformin hydrochloride:

Species : Rabbit

Result : Mild eye irritation

Magnesium stearate:

Species : Rabbit

Result : No eye irritation

Remarks : Based on data from similar materials

Ertugliflozin:

Result : Severe irritation

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Magnesium stearate:

Test Type : Maximization Test Routes of exposure : Skin contact Species : Guinea pig

Method : OECD Test Guideline 406

Result : negative

Remarks : Based on data from similar materials

Ertugliflozin:

Test Type : Local lymph node assay (LLNA)

Result : Not a skin sensitizer.

Germ cell mutagenicity

Not classified based on available information.

Components:

metformin hydrochloride:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)



Ertugliflozin / Metformin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 4.1
 30.09.2023
 590558-00018
 Date of first issue: 01.04.2016

Result: negative

Test Type: in vitro test

Test system: mouse lymphoma cells

Result: negative

Test Type: Chromosomal aberration Test system: Human lymphocytes

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Application Route: Oral

Result: negative

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion

Result: negative

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Result: negative

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Remarks: Based on data from similar materials

Ertugliflozin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Rat Result: negative



Ertugliflozin / Metformin Formulation

Version Date of last issue: 04.04.2023 Revision Date: SDS Number: 4.1 30.09.2023 590558-00018 Date of first issue: 01.04.2016

Carcinogenicity

Not classified based on available information.

Components:

metformin hydrochloride:

Species Mouse Exposure time 91 weeks

Dose 1500 mg/kg body weight

Result negative

Species Rat, male **Application Route** Oral

Exposure time 104 weeks

Dose 900 mg/kg body weight

Result negative

Species Rat, female

Application Route Oral

Exposure time 104 weeks

LOAEL 900 mg/kg body weight

Result negative

Target Organs Uterus (including cervix)

Remarks The mechanism or mode of action may not be relevant in hu-

mans.

Cellulose:

Species Rat **Application Route** Inaestion Exposure time 72 weeks Result negative

Ertugliflozin:

Species Mouse **Application Route** Oral Exposure time 2 Years Result negative

Species Rat **Application Route** Oral Exposure time 2 Years Result negative

Carcinogenicity - Assess-

Weight of evidence does not support classification as a carment

cinogen

Reproductive toxicity

Not classified based on available information.

Components:

metformin hydrochloride:



Ertugliflozin / Metformin Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 4.1 30.09.2023 590558-00018 Date of first issue: 01.04.2016

Effects on fertility : Test Type: Fertility

Species: Rat

Application Route: Oral

Fertility: NOAEL: 600 mg/kg body weight

Result: No effects on fertility.

Effects on fetal development : Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 600 mg/kg body weight

Result: No teratogenic effects.

Test Type: Embryo-fetal development

Species: Rabbit Application Route: Oral

Embryo-fetal toxicity.: NOAEL: 140 mg/kg body weight

Result: No teratogenic effects.

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

Result: negative

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the

reproduction/developmental toxicity screening test

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 422

Result: negative

Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Ingestion

Result: negative

Remarks: Based on data from similar materials

Ertugliflozin:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Oral

Fertility: NOAEL: 250 mg/kg body weight Remarks: Maternal toxicity observed. No significant adverse effects were reported

Test Type: Fertility/early embryonic development



Ertugliflozin / Metformin Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 4.1 30.09.2023 590558-00018 Date of first issue: 01.04.2016

Species: Rabbit

Application Route: Oral

Fertility: NOAEL: 200 mg/kg body weight

Remarks: No significant adverse effects were reported

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 50 mg/kg body weight Remarks: Adverse developmental effects were observed

Test Type: Embryo-fetal development

Species: Rabbit Application Route: Oral

Developmental Toxicity: NOAEL: 250 mg/kg body weight Remarks: No significant adverse effects were reported

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.

Components:

Ertugliflozin:

Routes of exposure : Oral

Target Organs : Kidney, Stomach, Prostate

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

metformin hydrochloride:

Species : Rat

NOAEL : 125 mg/kg Application Route : Oral Exposure time : 1 year

Remarks : No significant adverse effects were reported

Species : Rabbit
NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 1 Year

Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 50 mg/kg
Application Route : Subcutaneous

Exposure time : 2 year

Remarks : No significant adverse effects were reported



Ertugliflozin / Metformin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 4.1
 30.09.2023
 590558-00018
 Date of first issue: 01.04.2016

Cellulose:

Species : Rat

NOAEL : >= 9,000 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Magnesium stearate:

Species : Rat

NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Remarks : Based on data from similar materials

Ertugliflozin:

Species : Rat
LOAEL : 500 mg/kg
Application Route : Oral
Exposure time : 30 d

Species : Rat
LOAEL : 250 mg/kg
Application Route : Oral
Exposure time : 30 d
Target Organs : Kidney

Species : Rat
LOAEL : 25 mg/kg
Application Route : Oral
Exposure time : 180 d

Target Organs : Kidney, Bone, Stomach

Species : Rat LOAEL : 25 mg/kg Exposure time : 90 d

Target Organs : Kidney, Gastrointestinal tract, Prostate

Species : Dog
NOAEL : 150 mg/kg
Application Route : Oral
Exposure time : 270 d

Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 90 d

Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 28 d
Target Organs : Bone



Ertugliflozin / Metformin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 4.1
 30.09.2023
 590558-00018
 Date of first issue: 01.04.2016

Remarks : No significant adverse effects were reported

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

metformin hydrochloride:

Skin contact : Remarks: May irritate skin. Eye contact : Remarks: May irritate eyes.

Ingestion : Symptoms: Diarrhea, Nausea, Vomiting, Gastrointestinal dis-

comfort, flatulence, asthenia, Fatigue, Headache

Ertugliflozin:

Ingestion : Symptoms: The most common side effects are:, Headache,

constipation, Diarrhea, Nausea, urinary tract infection, muscle

pain, upper respiratory tract infection

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

metformin hydrochloride:

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 10 mg/l

Exposure time: 33 d

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 40 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l

Exposure time: 48 h

Remarks: Based on data from similar materials



Ertugliflozin / Metformin Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 4.1 30.09.2023 590558-00018 Date of first issue: 01.04.2016

Magnesium stearate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l

Exposure time: 48 h Method: DIN 38412

Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates

EL50 (Daphnia magna (Water flea)): > 1 mg/l

Exposure time: 47 h

Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials

No toxicity at the limit of solubility.

Toxicity to algae/aquatic

plants

EL50 (Pseudokirchneriella subcapitata (green algae)): > 1

mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

No toxicity at the limit of solubility.

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1

mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l

Exposure time: 16 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Ertugliflozin:

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 77 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 50

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 1 mg/l

Exposure time: 32 d

Method: OECD Test Guideline 210

Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 2.14 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Remarks: No toxicity at the limit of solubility.



Ertugliflozin / Metformin Formulation

Version Date of last issue: 04.04.2023 Revision Date: SDS Number: 4.1 30.09.2023 590558-00018 Date of first issue: 01.04.2016

Toxicity to microorganisms EC50: > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 1,000 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Persistence and degradability

Components:

metformin hydrochloride:

Biodegradability Result: rapidly degradable

Biodegradation: 50 % Exposure time: 2 hrs

Cellulose:

Biodegradability Result: Readily biodegradable.

Magnesium stearate:

Biodegradability Result: Not biodegradable

Remarks: Based on data from similar materials

Ertugliflozin:

Biodegradability Result: Not readily biodegradable.

> Biodegradation: 40.8 % Exposure time: 28 d

Bioaccumulative potential

Components:

metformin hydrochloride:

Partition coefficient: n-

octanol/water

log Pow: -2

Magnesium stearate:

Partition coefficient: n-

log Pow: > 4

octanol/water **Ertugliflozin:**

Partition coefficient: n-

log Pow: 2.47

octanol/water Mobility in soil

Components:

metformin hydrochloride:



Ertugliflozin / Metformin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 4.1
 30.09.2023
 590558-00018
 Date of first issue: 01.04.2016

Distribution among environ: log Koc: 4.3

mental compartments Method: OECD Test Guideline 106

Ertugliflozin:

Distribution among environmental compartments

log Koc: 2.88

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

NOM-002-SCT

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Federal Law for the control of chemical precursors, essential chemical products and machinery for producing capsules, tablets and pills.

Not applicable

The ingredients of this product are reported in the following inventories:

AICS : not determined



Ertugliflozin / Metformin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 4.1
 30.09.2023
 590558-00018
 Date of first issue: 01.04.2016

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Revision Date : 30.09.2023 Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

NOM-010-STPS-2014 : Mexico. Norm NOM-010-STPS-2014 on Chemicals Polluting

the Work Environment - Identification, Assessment and Con-

trol - Appendix 1 Occupational Exposure Limits

ACGIH / TWA : 8-hour, time-weighted average NOM-010-STPS-2014 / VLE- : Time weighted average limit value

PPT

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate: NOM - Official Mexican Norm: NTP - National Toxicology Program: NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety

Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/



Ertugliflozin / Metformin Formulation

VersionRevision Date:SDS Number:Date of last issue: 04.04.20234.130.09.2023590558-00018Date of first issue: 01.04.2016

The information is considered as correct, but not exhaustive, and will be used only as a guide, which is based in the current knowledge of the substance or mixture, and is applicable to proper safety precautions for the product.

MX/Z8